View Item 

Show simple item record

Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients
dc.contributor.authorBorges, Silvanaen_US
dc.contributor.authorDesta, Zeruesenayen_US
dc.contributor.authorJin, Yanen_US
dc.contributor.authorFaouzi, Azzouzen_US
dc.contributor.authorRobarge, Jason D.en_US
dc.contributor.authorPhilip, Santoshen_US
dc.contributor.authorNguyen, Anneen_US
dc.contributor.authorStearns, Vereden_US
dc.contributor.authorHayes, Danielen_US
dc.contributor.authorRae, James M.en_US
dc.contributor.authorSkaar, Todd C.en_US
dc.contributor.authorFlockhart, David A.en_US
dc.contributor.authorLi, Langen_US
dc.date.accessioned2013-04-08T20:50:12Z
dc.date.available2013-04-08T20:50:12Z
dc.date.issued2010-04en_US
dc.identifier.citationBorges, Silvana; Desta, Zeruesenay; Jin, Yan; Faouzi, Azzouz; Robarge, Jason D.; Philip, Santosh; Nguyen, Anne; Stearns, Vered; Hayes, Daniel; Rae, James M.; Skaar, Todd C.; Flockhart, David A.; Li, Lang (2010). "Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients." The Journal of Clinical Pharmacology 50(4). <http://hdl.handle.net/2027.42/97292>en_US
dc.identifier.issn0091-2700en_US
dc.identifier.issn1552-4604en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/97292
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherActivity Scoreen_US
dc.subject.otherCYP2D6en_US
dc.subject.otherInhibitionen_US
dc.subject.otherTamoxifenen_US
dc.titleComposite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patientsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherDivision of Biostatistics, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indianaen_US
dc.contributor.affiliationotherDepartment of Oncology, Johns Hopkins University, Baltimore, Marylanden_US
dc.contributor.affiliationotherDivision of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indianaen_US
dc.identifier.pmid20081063en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/97292/1/0091270009359182.pdf
dc.identifier.doi10.1177/0091270009359182en_US
dc.identifier.sourceThe Journal of Clinical Pharmacologyen_US
dc.identifier.citedreferenceGasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004; 351: 2827 – 2831.en_US
dc.identifier.citedreferenceDesta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004; 310: 1062 – 1075.en_US
dc.identifier.citedreferenceTyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics. 1997; 7: 375 – 379.en_US
dc.identifier.citedreferenceDahl ML, Johansson I, Palmertz MP, Ingelman‐Sundberg M, Sjoqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther. 1992; 51: 12 – 17.en_US
dc.identifier.citedreferenceHou ZY, Pickle LW, Meyer PS, Woosley RL. Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther. 1991; 49: 410 – 419.en_US
dc.identifier.citedreferenceSachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997; 60: 284 – 295.en_US
dc.identifier.citedreferenceZanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004; 369: 23 – 37.en_US
dc.identifier.citedreferenceIngelman‐Sundberg M, Daly AK, Nebert DW. Human Cytochrome P450 (CYP) Allele Nomenclature Committee Web site. www.imm.ki.seCYPalleles. Accessed December 24, 2009.en_US
dc.identifier.citedreferenceDahl ML, Johansson I, Bertilsson L, Ingelman‐Sundberg M, Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of the molecular genetic basis. J Pharmacol Exp Ther. 1995; 274: 516 – 520.en_US
dc.identifier.citedreferenceLundqvist E, Johansson I, Ingelman‐Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene. 1999; 226: 327 – 338.en_US
dc.identifier.citedreferenceMichelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007; 46: 242 – 251.en_US
dc.identifier.citedreferenceRau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants—a pilot study. Clin Pharmacol Ther. 2004; 75: 386 – 393.en_US
dc.identifier.citedreferenceSchillevoort I, de Boer, A, van der Weide, J, et al. Antipsychotic‐induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case‐control study. Pharmacogenetics. 2002; 12: 235 – 240.en_US
dc.identifier.citedreferenceShams ME, Arneth B, Hiemke C, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006; 31: 493 – 502.en_US
dc.identifier.citedreferenceSomogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther. 2007; 81: 429 – 444.en_US
dc.identifier.citedreferenceWuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol‐associated adverse effects. Clin Pharmacol Ther. 2002; 72: 429 – 437.en_US
dc.identifier.citedreferenceGoetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007; 101: 113 – 121.en_US
dc.identifier.citedreferenceKawanishi C, Furuno T, Kishida I, Matsumura T, Kosaka K. A patient with treatment‐resistant schizophrenia and cytochrome P4502D6 gene duplication. Clin Genet. 2002; 61: 152 – 154.en_US
dc.identifier.citedreferenceKawanishi C, Lundgren S, Agren H, Bertilsson L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse: a pilot study. Eur J Clin Pharmacol. 2004; 59: 803 – 807.en_US
dc.identifier.citedreferenceKirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004; 9: 442 – 473.en_US
dc.identifier.citedreferenceDalen P, Frengell C, Dahl ML, Sjoqvist F. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit. 1997; 19: 543 – 544.en_US
dc.identifier.citedreferencede Leon J, Dinsmore L, Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol. 2003; 23: 420 – 421.en_US
dc.identifier.citedreferenceKirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra‐rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007; 7: 257 – 265.en_US
dc.identifier.citedreferenceKoren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine‐prescribed mother. Lancet. 2006; 368: 704.en_US
dc.identifier.citedreferenceChou WH, Yan FX, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol. 2000; 20: 246 – 251.en_US
dc.identifier.citedreferenceFlockhart DA. Cytochrome P450 drug interactions. http:medicine.iupui.educlinpharmddis. Access December 24, 2009.en_US
dc.identifier.citedreferenceJin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005; 97: 30 – 39.en_US
dc.identifier.citedreferenceBorges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006; 80: 61 – 74.en_US
dc.identifier.citedreferenceCai WM, Nikoloff DM, Pan RM, et al. CYP2D6 genetic variation in healthy adults and psychiatric African‐American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J. 2006; 6: 343 – 350.en_US
dc.identifier.citedreferenceLi L, Pan RM, Porter TD, et al. New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes. Drug Metab Dispos. 2006; 34, 1411 – 1416.en_US
dc.identifier.citedreferenceZineh I, Beitelshees AL, Gaedigk A, et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol. Ther. 2004; 76: 536 – 544.en_US
dc.identifier.citedreferenceGaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008; 83: 234 – 242.en_US
dc.identifier.citedreferenceStearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003; 95: 1758 – 1764.en_US
dc.identifier.citedreferenceFood and Drug Administration. Guidance for industry drug interaction studies—study design, data analysis, and implications for dosing and labeling (Draft Guidance). September 2006. http:www.fda.govdownloadsDrugsGuidanceComplianceRegulatoryInformationGuidancesucm072101.pdf. Accessed December 24, 2009.en_US
dc.identifier.citedreferenceLaine K, Tybring G, Hartter S, et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001; 70: 327 – 335.en_US
dc.identifier.citedreferenceIngelman‐Sundberg M, Johansson I, Persson I, et al. Genetic polymorphism of cytochrome P450: functional consequences and possible relationship to disease and alcohol toxicity. EXS. 1994; 71: 197 – 207.en_US
dc.identifier.citedreferenceIngelman‐Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004; 25: 193 – 200.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
0091270009359182.pdf
Size:
528.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.